

Recently diagnosed with metastatic urothelial cancer (mUC)?

You may qualify to take part in the global TROPHY-U-01 clinical trial

Reasons to consider participating



You may receive standard treatment for mUC, the study drug sacituzumab govitecan, or a combination of both.



Study visits, treatments, and study-related lab work are provided at no cost to you.

Purpose of study



The purpose of the study is to find out if the study drug is effective and safe when taken alone or when combined with approved treatments for mUC.

You must be ≥ 18 years old and meet 1 of the criteria below:



Have not received any platinum-based chemotherapy.



Have received **4 but no more than 6 cycles of GEM+cisplatin.**



Cannot **receive cisplatin and have had no prior therapy** for your disease.

There are other requirements for participation; the study doctor will explain these to you. Based on your treatment history, you will be placed into one of the 3 study treatment groups if enrolled.



Now enrolling eligible patients

To join, ask your doctor or please contact your local study team:
